Keywords: مهار کننده چقدر است; Allogeneic hematopoietic cell transplantation; Graft-versus-host disease; Chronic GVHD; Interleukin-17A; JAK inhibitor;
مقالات ISI مهار کننده چقدر است (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده چقدر است; Allogeneic hematopoietic cell transplantation; Graft-versus-host disease; Chronic GVHD; Interleukin-17A; JAK inhibitor;
Keywords: مهار کننده چقدر است; Jak inhibitor; Ruxolitinib; SR graft-versus-host disease; SR-GVHD in children;
Keywords: مهار کننده چقدر است; JAK inhibitor; Myeloproliferative neoplasm; Overall survival; Ruxolitinib; Splenomegaly;
Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor
Keywords: مهار کننده چقدر است; Peficitinib; ASP015K; JAK (Janus kinase); JAK inhibitor; Immunomodulator; Crystal structures; WaterMap; Rheumatoid arthritis;
Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor
Keywords: مهار کننده چقدر است; JAK inhibitor; Rheumatoid arthritis; JAK1-selective; Collagen-induced arthritis mouse model; Adjuvant-induced arthritis rat model;
Emerging therapies for atopic dermatitis: JAK inhibitors
Keywords: مهار کننده چقدر است; atopic dermatitis; baricitinib; eczema; JAK inhibitor; ruxolitinib; systemic therapy; tofacitinib; CPK; creatine phosphokinase; Cr; creatinine; EASI; Eczema Area and Severity Index; JAK; Janus kinase; PASI; Psoriasis Area and Severity Index; STAT; signal
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia
Keywords: مهار کننده چقدر است; Chronic myeloid leukemia; JAK inhibitor; BCR-ABL; Tofacitinib; Imatinib;
Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis
Keywords: مهار کننده چقدر است; Extramedullary hematopoiesis; glomerulonephritis; membranous nephropathy; myeloproliferative disorder; myelofibrosis; JAK inhibitor; acute kidney injury (AKI); proteinuria; nephrotic syndrome; case report; kidney biopsy;
JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics
Keywords: مهار کننده چقدر است; JAK/STAT; T-cell malignancy; JAK inhibitor; ATLL; adult T-cell leukemia/lymphoma; γc; common gamma receptor dependent cytokine; HTLV-1; human T-cell lymphotropic virus-1; IL-2/IL-2R; interleukin 2/interleukin 2 receptor; JAK; Janus kinase; JAK3i; Janus k
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors
Keywords: مهار کننده چقدر است; JAK inhibitor; Pyrrolopyridazine; CIA efficacy; JAK1/3;
JAK inhibitors in dermatology: The promise of a new drug class
Keywords: مهار کننده چقدر است; alopecia areata; atopic dermatitis; baricitinib; JAK inhibitor; JAK-STAT; psoriasis; ruxolitinib; tofacitinib; vitiligo; AA; alopecia areata; AD; atopic dermatitis; AT; alopecia totalis; AU; alopecia universalis; CANDLE; chronic atypical neutrophilic derm
JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms
Keywords: مهار کننده چقدر است; JAK-STAT; Myeloproliferative neoplasm; JAK inhibitor; Ruxolitinib; Primary myelofibrosis;
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease
Keywords: مهار کننده چقدر است; Crohn's disease; Jak inhibitor; Filgotinib; TGF-β; SMAD7; Mongersen; Sphingosine-1-phosphate receptor; Ozanimod;
JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total BÂ cells
Keywords: مهار کننده چقدر است; JAK inhibitor; Adjuvant-induced arthritis; Th17; Treg; Memory BÂ cells; STAT3;
Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension
Keywords: مهار کننده چقدر است; Essential thromobocythemia; JAK inhibitor; Myelofibrosis; Polycythemia vera; Thrombosis;
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Keywords: مهار کننده چقدر است; Alopecia areata; Interferon gamma; JAK inhibitor; CANDLE syndrome; Autoimmune disease; Baricitinib; Gene expression profiling; Autoinflammatory
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
Keywords: مهار کننده چقدر است; Albumin; Cachexia; Cholesterol; JAK inhibitor; Weight;
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors
Keywords: مهار کننده چقدر است; JAK inhibitor; Pyrrolo[1,2-b]pyridazine; Janus kinase; JAK3; TYK2;
Janus kinase signaling activation mediates peritoneal inflammation and injury in vitro and in vivo in response to dialysate
Keywords: مهار کننده چقدر است; JAK/STAT; JAK inhibitor; MCP-1; periostin; peritoneal dialysis;
3-O-methylthespesilactam, a new small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells
Keywords: مهار کننده چقدر است; 3-O-methylthespesilactam; Sesquiterpenoid-alkaloid; Benzo[cd]indole; Anticancer; JAK inhibitor
Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma
Keywords: مهار کننده چقدر است; Allergic asthma; JAK inhibitor; Nanoparticle; Th2; Th17; Treg; JAK-STAT;